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The chromosomal translocation t(11;14)(q13;q32) fuses the IGH and CCND1 genes and leads to cyclin D1 overexpression. This
genetic abnormality is the hallmark of mantle cell lymphoma (MCL), but is also found in some cases of atypical chronic
lymphocytic leukemia (CLL), characterized by a poor outcome. For an unequivocal assessment of this specific chromosomal
rearrangement on interphase cells, we developed a set of probes for fluorescence in situ hybridization (FISH). Northern
blotting was performed for analysis of the cyclin D1 expression in 18 patients. Thirty-eight patients, with either a typical MCL
leukemic phase (17 patients) or atypical CLL with an MCL-type immunophenotype, i.e., CD191, CD51, CD23-/low, CD79b/
sIgM(D)11, and FMC71 (21 patients), were analyzed by dual-color interphase FISH. We selected an IGH-specific BAC probe
(covering the JH and first constant regions) and a commercially available CCND1 probe. An IGH–CCND1 fusion was detected in
28 of the 38 patients (17 typical MCL and 11 cases with CLL). Cyclin D1 was not overexpressed in two patients with typical
MCL and an IGH–CCND1 fusion. In view of the poor prognosis associated with MCL and t(11;14)-positive CLL, we conclude
that this set of probes is a valuable and reliable tool for a rapid diagnosis of these entities. Genes Chromosomes Cancer
23:175–182, 1998. r 1998 Wiley-Liss, Inc.
INTRODUCTION
Mantle cell lymphoma (MCL) is a non-Hodgkin’s
lymphoma (NHL) that was recently recognized as a
specific entity in the revised NHL classification
(Harris et al., 1994). The accuracy of this individual-
ization is confirmed by clinical studies, all of which
demonstrate the poor outcome of MCL patients
(Coiffier et al., 1995; Fisher et al., 1995; Stewart et
al., 1995; Teodorovic et al., 1995; Zucca et al., 1995).
The normal counterpart of these malignant cells is
well characterized (naive B-cells that home to and
reside in primary lymphoid follicles and the mantle
zones of secondary follicles). However, identifica-
tion of malignant lymphocytes such as MCL cells
may be a difficult challenge for pathologists. Al-
though different immunologic, cytogenetic, and
molecular characteristics may be useful for recogniz-
ing these malignant lymphocytes, none of them is
constant and specific. Leukemic phases are fre-
quent and may be inaugural in MCL. It may be
difficult to distinguish the morphology of circulat-
ing abnormal cells in MCL from those in atypical
chronic lymphocytic leukemia (CLL). Flow studies
cannot always differentiate between these cell
types. Like CLL cells, MCL cells coexpress the
T-cell antigen CD5, panB antigens (CD19, CD20,
and CD22), and surface IgM (and usually IgD). In
contrast, FMC7 positivity, strong expression of
B-cell receptor CD79b/sIg molecules, and weak
expression of CD23 (or none) are specific for MCL
cells (Lardelli et al., 1990; Matutes et al., 1994;
Segal et al., 1995; Garand and Robillard, 1996;
Weisenburger and Armitage, 1996). However, this
typical MCL immunophenotypic profile may be
encountered in some cases of typical CLL (Garand
and Robillard, 1996).
Cytogenetic analyses in MCL usually show a
t(11;14)(q13;q32), but approximately 40% of ana-
lyzed cases apparently lack this typical transloca-
tion (Leroux et al., 1991; Vandenberghe et al.,
1992). On chromosome 14, breakpoints occur within
the Ig heavy chain (IGH) gene, usually in the JH
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region. On chromosome 11, breakpoints are not
tightly clustered, but occur over at least 130 kb
upstream of the CCND1 gene, which encodes the
cyclin D1 protein (de Boer et al., 1993, 1995a,
1995b; Rimokh et al., 1993). Because of the dis-
persed 11q13 breakpoints, molecular studies (South-
ern blot or PCR experiments) fail to detect the
rearrangements in 30–50% of cases (de Boer et al.,
1993; Rimokh et al., 1994; Luthra et al., 1995).
Theoretically, the best diagnostic test is the demon-
stration of cyclin D1 overexpression by use of
Northern blotting (de Boer et al., 1993; Rimokh et
al., 1993). However, this test is time-consuming and
usually is not performed in routine analysis. Re-
cently, a new competitive RT-PCR-based approach
has been reported (Uchimaru et al., 1997). Despite
encouraging results, this technique needs to be
evaluated on a larger series of patients, which,
unfortunately, is usually not available in routine
laboratories.
In order to circumvent the lack of sensitivity of
molecular techniques, we have developed a fluores-
cence in situ hybridization (FISH) approach to
detect the IGH–CCND1 rearrangements on inter-
phase nuclei. After selection of adequate 14q32 and
11q13 probes, we have analyzed 38 patients with
either a leukemic phase of MCL or an atypical
CLL with an MCL-type immunophenotype.
MATERIALS AND METHODS
Patients
Seventeen patients with a histologic diagnosis of
MCL according to the REAL classification (Harris
et al., 1994) and a leukemic phase were selected for
this study. We also analyzed 21 patients cytologi-
cally diagnosed as atypical CLL (20 cases with
mixed-cell-type CLL and one patient with B-
prolymphocytic leukemia) (Bennett et al., 1989),
but with an immunophenotype characteristic of
MCL (i.e., CD191, CD51, CD232/low, CD79b/
sIgM(D)11, FMC71) (Matutes et al., 1994; Garand
and Robillard, 1996). Their clinical, morphologic,
immunologic, and molecular characteristics are sum-
marized in Tables 1 and 2. For 34 of these patients,
analyses were performed on frozen bone marrow (2
cases) or peripheral blood (32 cases) samples. In
two cases, we analyzed PB cytospins. In two other
patients, we used BM cytogenetic preparations.
Immunologic Analyses
Peripheral blood (n 5 35) or bone marrow (n 5 3)
mononuclear cells were isolated using Ficoll-
Hypaque and analyzed by dual-color fluorescence
flow cytometry (FACSCALIBUR, Beckton-Dickin-
son). Different combinations of monoclonal antibod-
ies—directly labeled with fluorescein isothiocya-







1 F 57 ADP, SMG PL MCL
2 M 42 ADP, SMG,
DT
PL MCL
3 F 74 ADP, SMG Pl MCL
4 M 59 SMG PL 1 PLY MCL ‘‘BL’’
5 M 66 ADP, SMG PL MCL
6 M 87 ADP PL 1 PLY MCL
7 F 41 ADP, SMG PL 1 PLY MOL
8 F 73 ADP, SMG,
liver
‘‘Blastoid’’ ND
9 F 73 ADP, SMG PL MCL




11 M 57 ADP, SMG PL 1 PLY MCL ‘‘BL’’
12 M 71 ADP, SMG PL 1 PLY MCL
13 M 57 ADP, SMG PL MCL
14 M 51 ADP, SMG,
skin
PL LPL
15 F 48 ADP, SMG,
liver
SL MCL
16 F 66 ADP, skin PL 1 PLY MCL
17 F 71 ADP, SMG,
liver
‘‘Blastoid’’ MCL ‘‘BL’’
18 F 85 None PL ND
19 M 69 None PL 1 PLY ND
20 M 69 SMG, liver PL 1 PLY ND
21 M 72 SMG PL 1 PLY LPL
22 F 94 SMG, DT,
CNS
PL ND
23 M 67 ADP, SMG,
liver
PL LPL
24 F 75 SMG PL 1 PLY SLL
25 M 73 SMG PL ND
26 F 82 None PL SLL
27 M 55 ADP, SMG PLY PLL
28 M 51 SMG PL 1 PLY ND
29 M 66 SMG PL 1 PLY ND
30 M 72 ADP, SMG PL ND
31 M 77 SMG PL ND
32 F 67 None PL ND
33 F 56 ADP, SMG PL MCL
34 M 74 SMG, liver SL ND
35 M 69 ADP, SMG PL MCL ‘‘BL’’
36 M 83 ADP, SMG PL ND
37 F 84 None PL ND
38 F 54 None PL ND
aADP 5 adenopathy; SMG 5 splenomegaly; DT 5 digestive tract;
CNS 5 central nervous system.
bPL 5 pleiomorphic lymphocytes; PLY 5 prolymphocytes; SL 5 small
monomorphic lymphocytes.
cND 5 not done; LPL 5 lymphoplasmacytic lymphoma; PLL 5
prolymphocytic leukemia; SLL 5 small lymphocytic lymphoma; MCL 5
mantle cell lymphoma; ‘‘BL’’ 5 blastoid variant.
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nate (FITC) or phycoerythrin (PE)—were used:
CD5/IOT1a-FITC and CD19/IOB4-PE (Immuno-
tech); CD23/B6-FITC (Coultronics) and CD22/
leu14-PE (Beckton-Dickinson); FMC7-FITC
(Seralab) and CD79b-PE (Immunotech). Surface Ig
expression (µ, d, g, k, and l chains) was analyzed
with FITC-goat F(ab’)2 polyclonal antibodies (Kall-
stad).
Probes
The 11q13 probe was purchased from Vysis. This
probe covers 300 kb, is centered on the CCND1
locus, and contains both MTC and FGF4 loci, but
not the FGF3 locus (Fig. 1). The 14q32 probe was
selected from a BAC library, using a J1–J6 cDNA
probe. Mapping of this probe was performed using
PCR with primers specific for the switch regions
Sµ, Sg, Sa, and Se, according to Bergsagel et al.
(1996). The 11q13 probe was directly labeled with
SpectrumOrange. The 14q32 probe was labeled
with biotin in a regular random priming reaction. In
order to test the accuracy of this set of probes, we
first tested them on two samples with a cytogeneti-
cally proved t(11;14) (patients 7 and 8) (Fig. 2).













1 A (IgD2) 64 48 ND R (A) 62
2 C 73 73 C2, N1, S1 R (A) 65
3 C 92 77 ND R (B) 94
4 C 87 85 N2 R (A) 85
5 A (CD52) 97 0 S1 R (A) 93
6 C 74 74 ND R (A) 80
7 C 90 90 C1, N1, S2 R (B) 90
8 A (IgD2) 97 91 C1, S2 R (A) 83
9 C 88 88 ND R (A) 79
10 C 75 75 N1 R (A) 68
11 C 61 57 N1 R (B) 60
12 C 85 85 N2 R (A) 82
13 C 78 76 ND R (A) 70
14 C 55 43 ND R (A) 51
15 C 65 61 N1 R (A) 60
16 C 79 79 ND R (A) 75
17 C 79 78 N1, S1 R (A) 80
18 C 78 75 N1 R (A) 73
19 C 50 48 N1 R (A) 45
20 C 89 89 N1 R (A) 91
21 C 77 69 N2, S2 NR 2
22 C 73 72 N1 R (A) 70
23 C 64 55 N2 NR 1
24 C 86 31 ND NR 3
25 A (IgD2) 88 88 ND NR 2
26 C 93 82 N2 NR 2
27 A (IgD2) 88 88 N2 NR 3
28 C 73 50 N2 NR 1
29 C 86 84 N1 R (A) 81
30 C 83 78 ND R (A) 92
31 C 55 55 ND R (A) 54
32 C 82 31 ND NR 1
33 C 71 70 ND R (A) 63
34 A (IgD2) 79 71 ND R (A) 84
35 C 73 70 ND R (A) 68
36 A (IgD2) 66 66 ND R (A) 60
37 C 41 41 ND NR 2
38 C 84 84 ND NR 2
aC 5 common (CD191, CD51, CD232/low, FMC71, CD79b11, sIgMD11); A 5 atypical (missing antigen).
bCells with a B-phenotype: CD191/CD221/sIg1.
cC1 5 presence of a t(11;14) in the karyotype; N1 5 cyclin D1 overexpression; S1 5 Southern blot rearrangement at MTC locus.
dR 5 rearrangement (fusion 11q13–14q32); NR, no rearrangement.
Configuration A corresponds to a split of the CCND1 probe; B, to the absence of a splice.
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Figure 1. Schematic representation of the probe mapping and configuration on interphase nuclei. The
lines and dots represent the 11q13 (red) and the 14q32 (green) probes.
Figure 2. Green signals correspond to the 14q32 probe, red signals to the 11q13 probe, and yellow
signals to the colocalization of the two probes. A: Hybridization on an MCL patient metaphase showing the
11q13 probe splitting and the colocalization of both probes on the der(14). B: A typical cell with a type A
IGH–CCND1 fusion. C: A typical cell with a type B IGH–CCND1 fusion. D: An atypical configuration with a
probable duplication of the der(14) (patient 30).
FISH
Thawed BM or PB cells were washed in PBS and
separated into two samples, one for immunologic
analysis and one for FISH analysis. The latter
sample was fixed three times in methanol/acetic
acid (3/1) and then dropped on slides. Slides were
incubated for 30 min in 2 3 SSC at 37°C and then
dehydrated. They were then denatured in 70%
formamide at 73°C for 90 sec and dehydrated in a
cold alcohol series. Two hundred nanograms of the
14q32 probe was mixed with 1 µg of Cot-1 DNA
(Gibco, Gaithersburg, MD), denatured for 5 min,
and preannealed at 37°C for 15–30 min. The 11q13
probe was denatured for 5 min and then mixed with
the 14q32 probe. The probes were then applied to
slides, covered with a coverslip, and sealed with
rubber cement. After overnight hybridization, slides
were washed in 2 3 SSC at 73°C for 5 min and then
rinsed in 2 3 SSC/0.1% Triton-X100. Detection
was performed using FITC-avidin for 10 min at
37°C. After a final wash in 2 3 SSC/0.1% Triton-
X100, nuclei were counterstained with DAPI.
One hundred to 200 nuclei were then scored
using an epifluorescence microscope (Leica)
equipped with a triple-band-pass filter. In order to
define the sensitivity of this set of probes, we tested
them on 10 control patients. For controls, we chose
five patients with non-B-cell hematologic malignan-
cies (3 acute myeloid leukemia patients and 2
chronic myelocytic leukemia patients in chronic
phase) to avoid any IGH rearrangement, and five
normal volunteers. We used bone marrow samples
from the five patients and peripheral mononuclear
cells from the volunteers. Slide preparation and
FISH experiments were performed under the same
conditions as for MCL samples.
Molecular Analyses
For 18 patients, RNA was extracted from PB
according to Chomczynski and Sacchi (1987). North-
ern blot analyses were performed with a cDNA
cyclin D1 probe, enabling the detection of the two
main transcript species of 4.5 and 1.2 kb. For each
patient, the RNA amount and quality were con-
trolled by use of a GAPDH-specific probe. We also
performed Southern-blot analyses by using an MTC-




According to the morphology and immunopheno-
type of circulating abnormal cells and the histopatho-
logic findings, patients were classified in two groups:
MCL in leukemic phase and atypical CLL with an
MCL immunophenotypic profile. Seventeen cases
fulfilled the histopathologic criteria for MCL (Har-
ris et al., 1994), including four ‘‘blastoid’’ variants.
In this group, circulating abnormal cells (mean5
9 3 103/µl; range, 3–600 3 103/µl) were pleiomor-
phic lymphocytes with irregular, cleaved, nucle-
olized nuclei in 14 patients. In addition, blastoid
cells were present in two cases histologically classi-
fied as blastoid MCL variant. One patient had small
monomorphic lymphocytes, which were morpho-
logically indistinguishable from common CLL. Flow
studies revealed a typical MCL profile in 15 cases.
IgD expression was absent in one case, and CD5
was negative in another.
In the second group, the initial absolute lympho-
cyte count was increased in all 21 patients (mean 5
21 3 103/µl; range, 7–133 3 103/µl), morphologi-
cally classified as mixed cell type CLL in 20 cases
and prolymphocytic leukemia (PLL) in one. Histo-
pathologic data were available for six of these cases:
three lymphoplasmocytoid lymphomas, two small
lymphocytic lymphomas, and one PLL. Circulating
abnormal lymphoid cells showed a typical MCL
immunophenotypic profile in 17 cases and absence
of IgD expression in four.
Validation of Probes
Fluorescence in situ hybridization analysis
showed bright green and red signals in each experi-
ment (Fig. 2). Analysis of the two samples with
t(11;14) revealed one green signal on the normal
chromosome 14, one red signal on each chromo-
some 11 [the normal one and the der(11)], and one
yellow signal on the der(14). On controls, in the
absence of IGH–CCND1 rearrangement, two green
signals (corresponding to the 14q32 probe) and two
red signals (corresponding to the 11q13 probe) were
detected. Only cells with yellow signals or colocal-
ized signals (without any interval between the two
signals) were considered positive for IGH–CCND1
fusion. In controls, we analyzed 200 to 300 nuclei/
control (2,700 nuclei total) and found colocalized
signals in 1.8–3.7% of the cells (mean false positiv-
ity 5 2.9%). Using this set of probes, the cutoff for
positivity was fixed at 5.9% (mean 1 3 S.D.).
In IGH–CCND1 rearrangements, two different
configurations were found (Fig. 1). The first configu-
ration (type A) was one green signal (normal chromo-
some 14), two red signals [one corresponding to the
normal chromosome 11 and one corresponding to
the der(11)], and one yellow signal [corresponding
to the colocalization of the two probes on the
der(14)]. An atypical form of this configuration was
found in one patient with two yellow signals instead
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of one (patient 30). The second configuration (type
B) was one normal green signal (normal chromo-
some 14), one red signal (normal chromosome 11),
and one yellow signal [der(14)]. The type A configu-
ration corresponds to a breakpoint on chromosome
11 between the MTC and FGF4 loci, therefore
splitting the probe. The patient with a variant form
probably shared a duplication of the der(14) chromo-
some. The type B configuration corresponds to a
break centromeric to the MTC locus, upstream from
the 11q13 probe.
t(11;14) in Patients
We found an IGH–CCND1 rearrangement in 28 of
the 38 patients (Table 2). Among the 28 patients
with colocalized signals, 25 displayed the type A
configuration and three displayed type B. Compari-
son of percentages of clonal cells as determined by
immunophenotype and percentages of cells with
fusion showed an excellent correlation (Table 2).
The IGH–CCND1 fusion was found by FISH in all
patients with MCL in leukemic phase, whereas
only half of atypical CLL patients (11/21) displayed
the rearrangement. In this latter group, a t(11;14)
was found on both conventional cytogenetic and
FISH analyses in one patient histologically classi-
fied as lymphoplasmacytic lymphoma.
Molecular Analyses
PCR experiments with the BAC probe showed
the presence of specific PCR products with the Sµ,
Sg, and Se primers, whereas no amplification was
obtained with the Sa primers. We concluded that
the probe maps within the JH, Cµ, Cg4, Cg2, and
Ce2 regions (Fig. 1). Among the 18 patients with
analyzable RNA, 11 had cyclin D1 overexpression,
all of them displaying 11q13/14q32 fusion. Cyclin
D1 was not detectable in two patients with typical
MCL in leukemic phase, despite an IGH–CCND1
fusion. In contrast, the five patients with atypical
CLL and a t(11;14) using FISH overexpressed
cyclin D1. Southern blot experiments using an
MTC-specific probe showed a rearrangement in
three cases, all of them displaying an IGH–CCND1
fusion. Among the three patients without any
rearrangement with this probe, two did show an
IGH–CCND1 fusion (one patient with each configu-
ration) and one did not show any fusion.
DISCUSSION
Patients with MCL have in common advanced
age, a marked male predominance, generalized
lymphadenopathy (including splenomegaly), fre-
quent BM involvement, and a poor outcome with
standard therapies (Garcia-Conde and Cabanillas,
1995; Pittaluga et al., 1995; Weisenburger and
Armitage, 1996). Even if typical cases are easily
recognized from morphologic and immunologic
analyses, this may be a difficult challenge for
pathologists in atypical cases or when no biopsy
specimen is available.
So far, four studies in which FISH was used to
detect t(11;14) have been reported. The first used a
dual-color FISH approach with 14q32- and 11q13-
specific cosmid probes (Monteil et al., 1996). How-
ever, this study had a poor sensitivity (23%). The
second study also used a dual-color technique, but
with 11q13 probes only (Coignet et al., 1996). Four
MCL samples were analyzed and were found to be
rearranged with this set of probes. The third
published study used a different FISH technique,
namely, fiber-FISH using 11q13- and 14q32-
specific probes (Vaandrager et al., 1996). These
investigators found an 11q13–14q32 rearrangement
in 19 of 20 MCL. However, this technique is not
used routinely. Finally, a recent study using FISH
with an 11q13 YAC probe on atypical CLL cases
showed that a t(11;14) was present in 25% of
patients (Cuneo et al., 1997). However, the use of
single-color FISH with an 11q13 probe does not
allow the differentiation of 11q13 rearrangements
from trisomy 11. Moreover, t(11;14) with break-
points centromeric to MTC cannot be detected
with this strategy.
In order to detect t(11;14) simply and reliably, we
developed an interphase FISH method by using a
commercially available large 11q13 probe and an
IGH-specific BAC probe. We chose this latter probe
because of its large size (.100 kb), enabling unerr-
ing detection on interphase cells (Fig. 2). This set
of probes gave clear, bright signals in every case. We
found an IGH–CCND1 fusion in 17 of 17 patients
with a documented typical MCL. This 100% posi-
tivity demonstrates the high diagnostic sensitivity
of this set of probes, which compares favorably with
other diagnostic techniques such as cytogenetics,
Southern blot, or PCR. In this series, cytogenetics
was performed on only three patients (because
routine cytogenetics is not performed for lympho-
mas in our institution). Interestingly, one of these
three patients with a normal karyotype displayed a
fusion by using FISH, reflecting difficulties to
interpret cytogenetic results when no abnormality
is found. Southern blotting was performed on six
patients, showing a rearrangement in three cases.
FISH showed a fusion in these three patients, but
also in two others. This discrepancy is explained by
the diversity of breakpoints on chromosome 11. We
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did not perform PCR, but several previous studies
showed that only about 50% of true MCL patients
are diagnosed by PCR, because of the wide disper-
sion of breakpoints on chromosome 11 (de Boer et
al., 1993; Rimokh et al., 1994; Luthra et al., 1995).
Moreover, this FISH technique is very easy to
perform and gives an accurate assessment in less
than 24 hr. Interestingly, two patients with a histo-
logically proven MCL did not overexpress cyclin
D1, as shown by the negative Northern blot. The
RNA amount and quality were carefully assessed.
In these two patients, Northern analysis with a
control GAPDH probe showed the presence of
correct amounts of undegraded RNA. Moreover,
FISH analysis showed an IGH–CCND1 fusion of
type A configuration; therefore, it did not differ
from other MCL cases. These two cases are true
t(11;14)-positive MCL patients with absence of
CCND1 overexpression. One possible explanation
could be an 11q13 breakpoint located downstream
of the CCND1 gene, but still splitting the probe.
We also found such a fusion in 11 of 21 patients
with an MCL-type immunophenotype, but with
absent or discordant histology. These patients have
either a leukemic MCL or an atypical CLL with
t(11;14). Atypical CLL probably represents a collec-
tion of different entities that should be separated.
Genetic abnormalities such as t(11;14) may be
common denominators to individualize new patho-
logical subgroups. Moreover, both MCL and atypi-
cal CLL with t(11;14) have a very poor prognosis
and could be grouped together as ‘‘mantle cell
leukemia,’’ as proposed by Neilson et al. (1996).
Thus, the demonstration of the IGH–CCND1 fusion
is essential in atypical CLL. Immunophenotyping
is clearly not a good technique for this purpose,
because half of the cases with a typical MCL
phenotype did not share the typical gene fusion.
This FISH technique could be performed system-
atically in patients with CLL and an MCL-type
immunophenotype, in order to better characterize
this type of B-cell malignancy, as previously pro-
posed (Hernandez et al., 1995; Cuneo et al., 1997).
In conclusion, interphase FISH using this set of
large probes allows a rapid and reliable assessment
of t(11;14). Such a set of probes would enable
large-scale studies for better definition of the inci-
dence and prognostic significance of the IGH–
CCND1 fusion in B-cell malignancies. Of special
interest is that it would allow for a better nosologic
definition of the so-called atypical CLL: the forms
with an IGH–CCND1 fusion might be considered as
MCL, and the forms without such a fusion could be
considered as typical CLL.
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